Varicella-zoster vaccine for the prevention of herpes zoster

New England Journal of Medicine

Volumn 356, Issue 13, 2007, Pages 1338-1343

  Kimberlin, David W ^a,b   Whitley, Richard J ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; GABAPENTIN; OPIATE; PLACEBO; VARICELLA ZOSTER VACCINE;

ARTICLE; CHICKENPOX; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CRANIAL NERVE PARALYSIS; DRUG COST; ENCEPHALITIS; ERYTHEMA; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; INJECTION SITE REACTION; MYELITIS; PAIN; PERIPHERAL PARALYSIS; PNEUMONIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SWELLING; UNITED STATES; VACCINATION;

EID: 34047185285     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct066061     Document Type: Article

References (46)

1. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002;347:340-6.
2. Straus SE, Reinhold W, Smith HA, et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med 1984;311:1362-4.
3. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003;70:Suppl 1:S111-S118.
4. Hope-Simpson RE. The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
5. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-14.
6. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
7. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310-6.
8. Advisory Committee on Immunization Practices. Considerations for shingles vaccine recommendations in the U.S.: record of the proceedings. Atlanta: Centers for Disease Control and Prevention, 2006. (Accessed March 12, 2007, at http://www.cdc. gov/nip/acip/minutes/acip-min-jun06.pdf.)
9. Gershon AA, Perkin RT. Herpes zoster. N Engl J Med 2000;343:222.
10. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
11. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45. [Erratum, N Engl J Med 2000;342:1063.]
12. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985;152:1172-81.
13. Rogers RS III, Tindall JP. Geriatric herpes zoster. J Am Geriatr Soc 1971;19:495-504.
14. Brown GR. Herpes zoster: correlation of age, sex, distribution, neuralgia, and associated disorders. South Med J 1976;69:576-8.
15. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
16. Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage 2000;20:50-8.
17. Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003;70:Suppl 1:S24-S30.
18. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006;24:1308-14.
19. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352:2266-7.
20. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42.
21. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-7.
22. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982;142:291-3.
23. Dolin R, Reichman RC, Mazur MH, Whitley RJ. NIH conference: herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978;89:375-88.
24. Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med 1997;157:1209-13.
25. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-26.
26. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-6.
27. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983;309:1434-40.
28. Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 1995;92:10980-4.
29. Esiri MM, Tomlinson AH. Herpes zoster: demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron microscopy. J Neurol Sci 1972;15:35-48.
30. Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 2001;17:151-60.
31. Zostavax. Whitehouse Station, NJ: Merck & Co., 2006 (package insert). (Accessed March 5, 2007, at http://www.fda.gov/CbER/label/zosmer052506LB.pdf.)
32. ProQuad. Whitehouse Station, NJ: Merck & Co., 2005 (package insert). (Accessed March 5, 2007, at http://www.fda. gov/CbER/label/mmrvmer090605LB.pdf.)
33. Varivax. Whitehouse Station, NJ: Merck & Co., 2005 (package insert). (Accessed March 5, 2007, at http://www.fda.gov/cber/label/varmer040505LBr.pdf.)
34. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-9.
35. Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45:Suppl 8:S41-S46.
36. Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998;178:Suppl 1:S109-S112.
37. Trannoy E, Berger R, Hollander G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-6.
38. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-7.
39. Kanazi GE, Johnson RW, Dworkin RH. Treatment of postherpetic neuralgia: an update. Drugs 2000;59:1113-26.
40. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988;38:1427-32.
41. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990;47:305-12.
42. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.
43. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
44. ACIP provisional recommendations for prevention of varicella. Atlanta: Centers for Disease Control and Prevention, 2006. (Accessed March 5, 2007, at http://www.cdc.gov/nip/vaccine/varicella/varicella_acip_ recs_prov_june_2006. pdf.)
45. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine two-dose varicella immunization schedule. Pediatrics (in press).
46. ACIP provisional recommendations for the use of zoster vaccine. Atlanta: Centers for Disease Control and Prevention, 2006. (Accessed March 5, 2007, at http://www.cdc.gov/nip/recs/provisional_ recs/zoster-11-20-06.pdf.)